U.S. Recombinant Protein Therapeutics Cdmo Market Size & Outlook
U.S. recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
U.S. recombinant protein therapeutics cdmo market highlights
- The U.S. recombinant protein therapeutics cdmo market generated a revenue of USD 6,877.3 million in 2023 and is expected to reach USD 16,978.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 13.8% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 6,877.3 million |
| Market revenue in 2030 | USD 16,978.6 million |
| Growth rate | 13.8% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, U.S. accounted for 32.9% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 16,978.6 million by 2030.
Interferons was the largest segment with a revenue share of 21.49% in 2023. Horizon Databook has segmented the U.S. recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
An increase in R&D activities and a rise in the number of drug approvals in the country are among the major factors supporting market growth. Moreover, the demand for medicines and effective treatment options is constantly growing due to the high prevalence of cancer, infectious diseases, immunological disorders, metabolic disorders, and hematological disorders in the country, which is contributing to the growth of the U.S. recombinant protein therapeutics CDMO market.
The U.S. recombinant protein therapeutics CDMO market is fragmented due to the presence of a significant number of players. Expansion, digitalization of services, and M&A activities are among the key strategies undertaken by most of these companies.
Furthermore, pharmaceutical companies in the region are collaborating with other companies to outsource business activities to improve the cost efficiency of production and focus more on product innovation.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
U.S. Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
